3471 - 3480 of 6467 Results
Title
Year
-
OPENTitle: Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodiesJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 7End Page: 9Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.11.008Best OA location URL: http://www.prd-journal.com/article/S1353802020308592/pdfCitation Count: 6
-
OPENTitle: Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 84Issue #:Start Page: 1End Page: 4Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.020Best OA location URL: https://doi.org/10.1016/j.parkreldis.2020.12.020Citation Count: 21
-
OPENTitle: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 79End Page: 85Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024Best OA location URL: http://www.prd-journal.com/article/S135380202100016X/pdfCitation Count: 84
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 7
-
OPENTitle: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI databaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007Best OA location URL: https://repositorio.uca.edu.ar/handle/123456789/11625Citation Count: 21
-
OPENTitle: Exploratory analysis of the genetics of impulse control disorders in Parkinson's disease using genetic risk scoresJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 74End Page: 77Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.003Best OA location URL: https://hal.archives-ouvertes.fr/hal-03298502Citation Count: 11
-
OPENTitle: Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 108End Page: 113Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.007Best OA location URL: http://hdl.handle.net/11380/1251595Citation Count: 37
- Plasma NfL, clinical subtypes and motor progression in Parkinson's disease2021OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Citation Count: 60
-
OPENTitle: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 25End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012Best OA location URL: http://www.prd-journal.com/article/S1353802021001450/pdfCitation Count: 22
-
OPENTitle: Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonistJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 196Issue #:Start Page: 108693End Page: 108693Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108693Best OA location URL: https://hdl.handle.net/11584/325357Citation Count: 26